DUBLIN, July 19, 2017 /PRNewswire/ -- Allergan plc
(NYSE: AGN) today announced that Joseph H.
Boccuzi has been appointed to its Board of Directors,
effective immediately. Mr. Boccuzi recently retired as a
Partner in the Global Life Sciences, Board and Chief Executive
Officer Practices at Spencer Stuart, following 24 years of service
with the global executive search and leadership consulting
firm.
"Talented people give Allergan an edge as we continue to build
our Bold culture and drive long-term sustainable growth," said
Brent Saunders, Chairman and Chief
Executive Officer of Allergan. "Joe
Boccuzi has a long track record of identifying great life
sciences leaders globally and successfully matching board-level and
executive talent with companies to drive long-term value."
"Our Board believes that one of its key roles is to oversee
development of organizational capabilities, and to focus on talent
management. Joe Boccuzi's
unique insights, leadership skills and experience are additive and
complementary to the diverse mix of professional experiences of our
board of directors," said Chris
Coughlin, Lead Independent Director. "I welcome Joe to our
board and look forward to his contributions as we work together to
advance the interests of Allergan shareholders."
"I was drawn to the Allergan board by its adroit,
forward-thinking and dynamic leadership team and Board of
Directors. It is an exciting time to join Allergan, and I look
forward to helping the Company achieve its full potential for
shareholders and society," said Boccuzi.
Mr. Boccuzi retired from Spencer Stuart in December 2016, after 24 years of service, where
he played a central role in establishing and building the firm's
Life Sciences Practice. He served in positions of increasing
responsibility within Spencer Stuart, most recently as a Partner in
the firm's Global Life Sciences, Board and Chief Executive Officer
Practices.
Prior to joining Spencer Stuart, Mr. Boccuzi worked in executive
search, venture capital and corporate management roles. He
served as a consultant with Paul R.
Ray & Company, an executive search firm. Prior to
that, he worked as a Financial Advisor for Merrill Lynch. Mr.
Boccuzi also held several leadership positions at National Patent
Development Corporation, a venture capital firm specializing in
medical technology and investment throughout the U.S. and
worldwide. While there, he managed four medical startup
operations serving as chief operating officer, board member and
adviser to the board of directors. Prior to that, Mr. Boccuzi
worked in sales for Xerox Corporation.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceutical, device,
biologic, surgical and regenerative medicine products for patients
around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of
research and development, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. With this approach, Allergan has built one of the
broadest development pipelines in the pharmaceutical industry with
70+ mid-to-late stage pipeline programs currently in
development.
Allergan's success is powered by our more than 18,000 global
colleagues' commitment to being Bold for Life. Together, we build
bridges, power ideas, act fast and drive results for our customers
and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective on existing trends and
information as of the date of this release. Actual results may
differ materially from Allergan's current expectations depending
upon a number of factors affecting Allergan's business. These
factors include, among others, the difficulty of predicting the
timing or outcome of FDA approvals or actions, if any; the impact
of competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Annual Report
on Form 10-K for the year ended December 31,
2016 and Allergan's Quarterly Report on Form 10-Q for the
period ended March 31, 2017. Except
as expressly required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements.
CONTACTS:
Allergan:
Investors:
Daphne
Karydas
(862) 261-8006
Media:
Mark Marmur
(862) 261-7558
View original content with
multimedia:http://www.prnewswire.com/news-releases/joseph-h-boccuzi-appointed-to-allergan-plc-board-of-directors-300490515.html
SOURCE Allergan plc